Comprehensive molecular impact mapping of common and rare variants at GWAS loci
Source check: Source checked. Not independent scientific confirmation.
Finding: PMC labels this bioRxiv Version 1, posted 2025-06-06. Results identify DNACipher/DVIM as the sequence-to-function model and variant-prioritization method; T1D credible sets shrink from mean 24 to 1.4 variants and predictions are supported by single-nucleus ATAC-seq and luciferase assays. This is a preprint, not a peer-reviewed publication.
Technology: DNACipher
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- PMC labels this bioRxiv Version 1, posted 2025-06-06. Results identify DNACipher/DVIM as the sequence-to-function model and variant-prioritization method; T1D credible sets shrink from mean 24 to 1.4 variants and predictions are supported by single-nucleus ATAC-seq and luciferase assays.
- Test and result
- PMC labels this bioRxiv Version 1, posted 2025-06-06. Results identify DNACipher/DVIM as the sequence-to-function model and variant-prioritization method; T1D credible sets shrink from mean 24 to 1.4 variants and predictions are supported by single-nucleus ATAC-seq and luciferase assays.
- Limitation / still unknown
- No prospective clinical benefit or broader external validity is established by the documented study. Affiliation was not stated in the reviewed material.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12157646/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.